EUVIMEDEUVIMED entdecken
Klinische StudieVergleichsstudieOpen Access · CC BY 4.0

Comparison of [18F]DCFPyL and [18F]FAPI-74 PET/CT imaging in metastatic prostate cancer

Anniina Hyväkkä, Marko Seppänen, Maria Sundvall, Veera Sivonen, Kalle Mattila, Mikael Anttinen, Otto Ettala, Mikael Högerman, Anna Kirjavainen, Olli Eskola, Sarita Forsback, Virva Saunavaara und 5 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-08028-5 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Anniina Hyväkkä und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and FICAN West Cancer Center, University of Turku and Turku University Hospital, Turku, Finland. Hauptthemen laut MEDLINE: Lysine, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Tyrosine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Turku.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To compare prostate-specific membrane antigen (PSMA) and fibroblast activation-protein inhibitor (FAPI) targeted PET/CT imaging to assess possible theranostic combination strategies of both tracers in metastatic prostate cancer (mPC).

Methods

This prospective study enrolled patients with mPC who underwent long-axial field-of-view whole-body PET/CT with 18 F-DCFPyL and 18 F-FAPI-74 within two weeks. Fifteen patients had hormone sensitive (mHSPC) and 24 castration-resistant (mCRPC) disease. Scans were reviewed according to predefined criteria, with up to five metastases per anatomical region evaluated. Lesions were categorized in four groups as skeletal, pelvic nodal, extrapelvic nodal, or visceral. SUVmax and volumetric parameters were measured for each lesion and at the patient level.

Results

A total of 1365 lesions were identified in 39 patients. 18 F-DCFPyL PET/CT detected 1351 lesions (99%). In contrast, 18 F–FAPI-74 identified only 788 (58%) lesions in the PSMA-guided analysis and 523 (38%) lesions in the independent analysis. Median lesion SUVmax was higher for PSMA (24) than for FAPI (5.4) (p < 0.001). Visceral metastases constituted 3% of lesions with both tracers and tended to be more often FAPI-avid (64%) compared to other lesion groups. Only 14 (1%) of lesions were FAPI-positive and PSMA-negative. In whole-tumor burden analysis, median tracer-positive tumor volume on 18 F-DCFPyL PET/CT was 85 mL and on 18 F-FAPI-74 PET/CT only 10 mL (p < 0.001).

Conclusion

In mPC, PSMA PET/CT remains the preferred molecular imaging method. Our findings suggest only a limited role of FAPI radioligand therapy. FAPI theranostics should focus on patients with visceral metastases and specific histological subtypes beyond acinar adenocarcinoma. Clinical Trial Registration: EudraCT 2022–003788-13. Registered 21 September 2023

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LysinePositron Emission Tomography Computed TomographyProstatic NeoplasmsTyrosineUreaAgedAged, 80 and overHumansMaleMiddle AgedAntigens, SurfaceFibroblast Activation Protein AlphaFluorine RadioisotopesMembrane ProteinsNeoplasm MetastasisProspective StudiesRadiopharmaceuticalsGlutaratesPyridines

Stichwörter der Autor:innen

18F-DCFPyL18F-FAPI-74Fibroblast activation protein (FAP)PET/CT.Prostate cancerProstate-specific membrane antigen (PSMA)

Substanzen

Antigens, SurfaceFibroblast Activation Protein AlphaFluorine RadioisotopesLysineMembrane ProteinspiflufolastatRadiopharmaceuticalsTyrosineUreaGlutarates

Autor:innen und Institutionen

  • Department of Oncology and FICAN West Cancer Center, University of Turku and Turku University Hospital, Turku, Finland.
  • Department of Clinical Physiology, Nuclear Medicine and Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.
  • Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
  • Department of Urology, University of Turku and Turku University Hospital, Turku, Finland.
  • Radiopharmaceutical Chemistry, Turku PET Centre, University of Turku, Turku, Finland.
  • Department of Medical Physics and Turku PET Centre, Turku University Hospital, Turku, Finland.

Förderung

  • University of Turku

Zitieren

APA

Hyväkkä, A., Seppänen, M., Sundvall, M., Sivonen, V., Mattila, K., Anttinen, M., Ettala, O., Högerman, M., Kirjavainen, A., Eskola, O., Forsback, S., Saunavaara, V., Arvola, S., Kilpinen, K., Taimen, P., Malaspina, S., & Minn, H. (2026). Comparison of [18F]DCFPyL and [18F]FAPI-74 PET/CT imaging in metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08028-5

Vancouver

Hyväkkä A, Seppänen M, Sundvall M, Sivonen V, Mattila K, Anttinen M, et al. Comparison of [18F]DCFPyL and [18F]FAPI-74 PET/CT imaging in metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08028-5

BibTeX
@article{Hyvkk2026,
  author = {Hyväkkä, Anniina and Seppänen, Marko and Sundvall, Maria and Sivonen, Veera and Mattila, Kalle and Anttinen, Mikael and Ettala, Otto and Högerman, Mikael and Kirjavainen, Anna and Eskola, Olli and Forsback, Sarita and Saunavaara, Virva and Arvola, Samuli and Kilpinen, Kusti and Taimen, Pekka and Malaspina, Simona and Minn, Heikki},
  title = {Comparison of [18F]DCFPyL and [18F]FAPI-74 PET/CT imaging in metastatic prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-08028-5}
}
Kostenlos starten →